• Home
• 2019 General Session
• H.B. 251

H.B. 251 Drug Diversion Reporting Requirements

• Bill Text
• Status
• Hearings/Debate

Bill Sponsor: Rep. Eliason, Steve

Floor Sponsor: Sen. Bramble, Curtis S.

• Drafting Attorney: Chelsea Grant
• Fiscal Analyst: Maddy Oritt

---

• Bill Text
  • Introduced
  • Amended
    • Amended Pages Only
  • Enrolled (Currently Displayed)

---

• Related Documents
  • Fiscal Note
  • House Transmittal Letter 1
  • House Transmittal Letter 2
  • Senate Transmittal Letter 1
  • Senate Transmittal Letter 2
  • House Committee Amendment 1(passed)
  • House Committee Amendment 2(passed)
  • House Committee Amendment 3(passed)
  • Senate Committee Amendment 4(passed)
  • Agency Perf Note

---

• Information
  • Last Action: 27 Mar 2019, Governor Signed
  • Last Location: Lieutenant Governor's office for filing
  • Effective Date: 14 May 2019
  • Session Law Chapter: 377

---

• Similar Bills
  • Controlled Substances
  • Health
  • Criminal Code
  • Crimes
  • Law Enforcement and Criminal Justice

---

Enrolled

Printer Friendly

H.B. 251

1     DRUG DIVERSION REPORTING REQUIREMENTS
2     2019 GENERAL SESSION
3     STATE OF UTAH
4     Chief Sponsor: Steve Eliason
5     Senate Sponsor: Curtis S. Bramble
6     

---

7     LONG TITLE
8     General Description:
9          This bill relates to the duty to report drug diversion.
10     Highlighted Provisions:
11          This bill:
12          ▸     defines terms; and
13          ▸     makes it a class B misdemeanor to knowingly fail to report known or suspected
14     drug diversion to law enforcement, unless reporting would violate HIPAA.
15     Money Appropriated in this Bill:
16          None
17     Other Special Clauses:
18          None
19     Utah Code Sections Affected:
20     ENACTS:
21          76-10-2203, Utah Code Annotated 1953
22     

---

23     Be it enacted by the Legislature of the state of Utah:
24          Section 1. Section 76-10-2203 is enacted to read:
25          76-10-2203. Duty to report drug diversion.
26          (1) As used in this section:
27          (a) "Diversion" means a practitioner's transfer of a significant amount of drugs to
28     another for an unlawful purpose.
29          (b) "Drug" means a Schedule II or Schedule III controlled substance, as defined in

---

30     Section 58-37-4, that is an opiate.
31          (c) "HIPAA" means the same as that term is defined in Section 26-18-17.
32          (d) "Opiate" means the same as that term is defined in Section 58-37-2.
33          (e) "Practitioner" means an individual:
34          (i) licensed, registered, or otherwise authorized by the appropriate jurisdiction to
35     administer, dispense, distribute, or prescribe a drug in the course of professional practice; or
36          (ii) employed by a person who is licensed, registered, or otherwise authorized by the
37     appropriate jurisdiction to administer, dispense, distribute, or prescribe a drug in the course of
38     professional practice or standard operations.
39          (f) "Significant amount" means an aggregate amount equal to, or more than, 500
40     morphine milligram equivalents calculated in accordance with guidelines developed by the
41     Centers for Disease Control and Prevention (CDC).
42          (2) An individual is guilty of a class B misdemeanor if the individual:
43          (a) knows that a practitioner is involved in diversion; and
44          (b) knowingly fails to report the diversion to a peace officer or law enforcement
45     agency.
46          (3) Subsection (2) does not apply to the extent that an individual is prohibited from
47     reporting by 42 C.F.R. Part 2 or HIPAA.